Oncotarget: A Peer-Reviewed Journal That is Changing the Landscape of Cancer Research

Through its parent journal, Impact Journals, Oncotarget publishes scientific research findings on oncology and other medical-related fields every week. Since it published its first article seven years ago, the journal has gone ahead to publish thousands of other insightful and peer-reviewed articles. All the articles are in English, which makes them readable by a huge population across the world. Besides that, Oncotarget is categorized under open-access journals, meaning that anyone interested in scientific knowledge has a fair chance of accessing it in the journal.

The Team

The team behind Oncotarget is not only qualified and dedicated but also talented and with an impressive research record. Led by chief editors, Prof. Andrei V. Gudkov and his counterpart Prof. Mikhail Blagoskloklonny, the team ensures that the articles circulated in the journal meet the threshold of high quality and exhaustively informational. The chief editors are renowned professors at Roswell Park Cancer Institute in Buffalo, New York.Blagosklonny has authored more than 250 articles in peer-reviewed journals. Andrei Gudkov, on the other hand, has made an immense contribution to the study of cancer therapies, particularly in drug discovery and molecular targets.

The Impact Factor

In its first year of publication, Oncotarget recorded an impact factor (IF) of 4.78 and was being received by readers across 493 cities, which was impressive for a new entrant. A year later, the reception had increased to 1450 cities, and its IF had risen to 6.636. 2013 is the year when Oncotarget registered the highest impact factor, recording a 6.627. In the same year, the number of cities receiving the journal rose to over 2200 cities. The following year, the journal had an IF of 6.359, a drop but still consistently high. The reception at this time was almost hitting 4,000 cities. Today, the impact factor for Oncotarget stands at 5.168 while the reception has grown to more than 30,000 cities. Comparatively, Oncotarget’s reception has multiplied by almost 100 times over the seven years of its existence.

Source of the article : http://gettingstronger.org/tag/mikhail-blagosklonny/